Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 15 |
| Active Pipeline (Recruiting Now) | 5 (2) |
| Completed vs Stopped Early | 10 / 0 (0.0%) |
| Median Closed Actual Enrollment | 28 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Columbia University Irving Medical Center | New York, NY | 8 |
| Children's Hospital Colorado | Aurora, CO | 6 |
| Vanderbilt University Medical Center | Nashville, TN | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06760546 | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | Phase III | RECRUITING |
| NCT06046443 | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Rhythm Pharmaceuticals Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.